Therapeutic Potential in Wound Healing of Allogeneic Use of Equine Umbilical Cord Mesenchymal Stem Cells

Ailén Iribarne,María Belén Palma,Laura Andrini,Fernando Riccillo,Delfina Rodriguez,Martín Casella,Felipe Garay,Julieta Spoto Zabala,Leandro Mazza,Adriana Muro,Guillermo Buero,Santiago G. Miriuka,Edgardo Carosella,Marcela N. García
DOI: https://doi.org/10.3390/ijms25042350
IF: 5.6
2024-02-16
International Journal of Molecular Sciences
Abstract:Wound healing after skin injury is a complex process, particularly in equines where leg wounds are prevalent and their repair is complicated due to the anatomical characteristics. Conventional treatments are not effective enough. The umbilical cord offers an unlimited source of adult mesenchymal stem cells (ucMSCs) from Wharton's jelly tissue. The present study aims to demonstrate the safety and therapeutic potential of the allogeneic use of equine ucMSCs (e-ucMSCs) in the healing of severe equine leg wounds. The methods employed were the isolation, culture and expansion of e-ucMSCs. Flow cytometry and a PCR assay were used for cell characterization. This study included an immunomodulation assay, a murine pre-clinical trial and the first phase of an equine clinical trial. Our results showed that e-ucMSCs express a functional HLA-G homolog, EQMHCB2. In the immunomodulation assay, the e-ucMSCs inhibited the proliferation of activated equine peripheral blood mononuclear cells (e-PBMCs). In the murine pre-clinical trial, e-ucMSCs reduced healing time by 50%. In the equine clinical trial, the injection of e-ucMSCs into severe leg lesions improved the closure time and quality of the tissues involved, regenerating them without fibrous tissue scar formation. In conclusion, the results of this study suggest that e-ucMSCs can be used allogeneically for wound healing by creating a tolerogenic environment.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
### Problems the Paper Aims to Address This paper aims to explore the safety and therapeutic potential of allogeneic use of equine umbilical cord mesenchymal stem cells (e-ucMSCs) in treating severe leg wounds in horses. Specifically, the researchers hope to verify the following aspects: 1. **Safety**: Assess the immune response after in vivo transplantation of e-ucMSCs to ensure they do not cause significant immune rejection or inflammatory reactions. 2. **Therapeutic Potential**: Through a series of experiments, including cell characterization, immunomodulation tests, preclinical trials in mice, and clinical trials in horses, verify the effectiveness of e-ucMSCs in promoting wound healing. ### Background The repair of leg wounds in horses is a complex process, especially due to anatomical features that make these wounds difficult to heal. Traditional treatment methods are limited in effectiveness, often leading to slow healing and the formation of fibrous scars. These issues not only affect the horse's athletic performance but can also result in high morbidity and long-term functional impairment. ### Research Methods 1. **Cell Isolation and Culture**: Isolate e-ucMSCs from the equine umbilical cord and perform culture and expansion. 2. **Cell Characterization**: Confirm the surface markers and gene expression of e-ucMSCs through flow cytometry and PCR analysis. 3. **Immunomodulation Tests**: Evaluate the inhibitory effect of e-ucMSCs on the proliferation of activated equine peripheral blood mononuclear cells (e-PBMCs). 4. **Preclinical Trials in Mice**: Transplant e-ucMSCs into a skin wound model in immunocompetent mice to observe their effect on wound healing. 5. **Clinical Trials in Horses**: Administer e-ucMSCs injection treatment to four injured horses to assess their effectiveness in actual clinical applications. ### Main Findings 1. **Cell Characterization**: e-ucMSCs primarily express CD90, indicating their undifferentiated state. 2. **Immunomodulatory Effect**: e-ucMSCs can significantly inhibit the proliferation of e-PBMCs, demonstrating good immunomodulatory capacity. 3. **Preclinical Trials in Mice**: e-ucMSCs significantly accelerated the healing process of skin wounds in mice, reducing the healing time by approximately 50%. 4. **Clinical Trials in Horses**: e-ucMSCs injection treatment significantly improved the healing time and tissue quality of severe leg wounds in horses, promoting scar-free regeneration. ### Conclusion The research results indicate that e-ucMSCs have good safety and therapeutic potential in allogeneic applications, capable of promoting the healing of severe leg wounds in horses while creating a tolerant environment to avoid immune rejection reactions. This finding provides important scientific evidence for the development of new functional tissue repair therapies.